Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VHH-based KappaLink platform
- Development stage
- Preclinical
- Lead developer
- Cerberus Therapeutics
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
The VHH-based KappaLink platform is a preclinical-stage therapeutic technology developed by Cerberus Therapeutics. It utilizes single-domain antibodies (VHHs or nanobodies) engineered to form an adduct that binds the immunoglobulin kappa (Igκ) light chain present on all naturally circulating immunoglobulins (including IgG, IgM, IgA, and IgE). This binding brings together infected cells and a diverse set of Fc receptor–positive effector cells. The result is rapid and effective activation of both B cell and T cell immune responses. The primary aim of the platform is to treat and prevent infections by leveraging endogenous antibody pools for broad immune engagement[7][9]. VHHs are derived from camelid heavy-chain-only antibodies; they are small, robust antigen-binding fragments with high stability and versatility in engineering[1][2]. The modularity of the KappaLink approach allows for potential applications across infectious diseases where enhanced immune recruitment is beneficial.
- Brand names
- VHH-based KappaLink platform
- Other names
- KappaLinkVHH-KappaLinkCerberus Therapeutics KappaLink platform
02
Targets
Immunoglobulin light chain
Beyond the preview
Go deeper on VHH-based KappaLink platform.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VHH-based KappaLink platform.